GPCR therapeutic monoclonal antibodies

CCR8 Targeting: A Promising Strategy for Cancer Immunotherapy and Beyond
SYnAbs has developed therapeutic monoclonal antibodies to CCR8 biomarker to deplete Treg and block the internalization of CCL1-CCR8 as immunotherapy for oncology diseases
SYnAbs signs a research agreement with Domain Therapeutics to discover therapeutic antibodies on GPCRs
SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications

G protein-coupled endothelin receptors and their natural and therapeutic ligands
From the discovery of an unique peptide ligand to the clinical relevance of ETA and ETB receptors and the current therapeutic pipeline of small molecules and monoclonal antibodies targeting these GPCR transmembrane proteins
Therapeutic trends of G protein-coupled receptor drugs as Antibody Drug Conjugates candidates
SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.

CX3CR1, GPCR CX3C chemokine receptor 1 (CX3CR1): transmembrane receptor of therapeutic interest?
SYnAbs discovers antibodies to transmembrane proteins including GPCR chemokine receptors thanks to unique cell immunization technology and expertise
Immuno-Oncology Therapeutic Potential of Adenosine Receptors: Targeting the Purinergic Pathway
SYnAbs develops therapeutic monoclonal antibodies with agonistic or antagonistic effects to highly homologous G Protein-Coupled Receptors transmembrane proteins

C3a and C5a anaphylatoxin receptors, therapeutic GPCR targets of the complement system
SYnAbs are unique therapeutic effector monoclonal antibodies targeting anaphylatoxin C3aR GPCR. First-in-class functional antibody targeting complex transmembrane proteins and G protein-coupled receptors.
Therapeutic targets of the complement system
The Complement System and its druggable targets by antibodies: C3aR, C5aR GPCR membrane receptors, C3, C4, C5 ligands

Orphan GPCR and their untapped therapeutic potential: the next wave of antibody drug targets?
Untapped therapeutic potential of orphan GPCR and SYnAbs functional monoclonals anti-GPCR. Generation of new antibody therapeutics targeting orphan membrane receptors.
CC chemokine receptors: latest news on Beta chemokine receptor therapeutics
SYnabs generate therapeutic monoclonal antibodies against CC chemokine receptors thanks to DNA, cell immunization strategies, unique rat-LOU species and proprietary adjuvant

Show more